ReviewBiosensors & bioelectronics2016
Towards detection and diagnosis of Ebola virus disease at point-of-care.
Review in Biosensors & bioelectronics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 149 citations in OpenAlex.
- Review
- Specific and visual detection of EBOV based on a one-pot RT-RAA-CRISPR/Cas12a assay.Virologica Sinica · 2025Article
- Evaluating the impact of trade-offs in diagnostic test accuracy, time-to-isolation, and accessibility on outbreak response for the Ebola virus: a mathematical modeling study.BMC infectious diseases · 2025Article
- Electrochemical detection of extracellular vesicles for early diagnosis: a focus on disease biomarker analysis.Extracellular vesicles and circulating nucleic acids · 2024Review
- Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024Review
- Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.NPJ systems biology and applications · 2023Review
- Efficiency of Field Laboratories for Ebola Virus Disease Outbreak during Chronic Insecurity, Eastern Democratic Republic of the Congo, 2018-2020.Emerging infectious diseases · 2023Article
- Article
- Paper based microfluidic devices: a review of fabrication techniques and applications.The European physical journal. Special topics · 2023Review
- Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens.Biosensors & bioelectronics · 2022Article
- Enhancement of the Detection Performance of Paper-Based Analytical Devices by Nanomaterials.Molecules (Basel, Switzerland) · 2022Review
- Metal Organic Frameworks as Biosensing Materials for COVID-19.Cellular and molecular bioengineering · 2021Review
- Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.Microbial pathogenesis · 2021Review
- The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management.Materials today. Chemistry · 2021Review
- Development and validation of portable, field-deployable Ebola virus point-of-encounter diagnostic assay for wildlife surveillance.One health outlook · 2021Article
- Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases.Biosensors & bioelectronics · 2021Review
- Functionalized terahertz plasmonic metasensors: Femtomolar-level detection of SARS-CoV-2 spike proteins.Biosensors & bioelectronics · 2021Article
- Pooled Analysis of the Accuracy of Xpert Ebola Assay for Diagnosing Ebola Virus Infection.BioMed research international · 2021Review
- Aspects of Point-of-Care Diagnostics for Personalized Health Wellness.International journal of nanomedicine · 2021Review
- Biosensors for the Detection of Bacterial and Viral Clinical Pathogens.Sensors (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Ebola outbreak-2014 (mainly Zaire strain related Ebola virus) has been declared most widely spread deadly persistent epidemic due to unavailability of rapid diagnostic, detection, and therapeutics. Ebola virus disease (EVD), a severe viral hemorrhagic fever syndrome caused by Ebola virus (EBOV) is transmitted by direct contact with the body fluids of infected person and objects contaminated with virus or infected animals. World Health Organization (WHO) has declared EVD epidemic as public health emergency of international concern with severe global economic burden. At fatal EBOV infection stage, patients usually die before the antibody response. Currently, rapid blood tests to diagnose EBOV infection include the antigen or antibodies capture using ELISA and RNA detection using RT/Q-PCR within 3-10 days after the onset of symptoms. Moreover, few nanotechnology-based colorimetric and paper-based immunoassay methods have been recently reported to detect Ebola virus. Unfortunately, these methods are limited to laboratory only. As state-of-the art (SoA) diagnostics time to confirm Ebola infection, varies from 6h to about 3 days, it causes delay in therapeutic approaches. Thus developing a cost-effective, rapid, sensitive, and selective sensor to detect EVD at point-of-care (POC) is certainly worth exploring to establish rapid diagnostics to decide therapeutics. This review highlights SoA of Ebola diagnostics and also a call to develop rapid, selective and sensitive POC detection of EBOV for global health care. We propose that adopting miniaturized electrochemical EBOV immunosensing can detect virus level at pM concentration within ∼40min compared to 3 days of ELISA test at nM levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.